News

Press Release: Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Kinea Bio receives Phase 1 NIH Small Business Innovation Research grant for $300,000 to research DM1.

Kinea's lead scientists publish groundbreaking paper on SIMPLI-GT technology.

Kinea Bio receives Phase 2 NIH Small Business Innovation Research grant for $1.96M.

Kinea co-founder Jeffrey Chamberlain receives the Outstanding Achievement Award from the American Society of Gene and Cell Therapy: the society’s highest honor.

Kinea's lead scientists publish impactful review on DMD gene therapy.

Kinea awarded pilot grants by University of Washington’s Center for Translational Muscle Research, and the Myotonic Dystrophy Foundation.

Chief Operating Officer Seung Wook Oh, PhD authors review article on non-viral gene therapy delivery for Duchenne Muscular Dystrophy

A Breakthrough Gene Therapy Strategy for Kinea's Lead Program, DMD, Published in Nature

Kinea Selected for Fast-Track NIH Small Business Innovation Research Funding

Kinea Bio Presents at Life Science Innovation Northwest Annual Conference

Jeffrey Chamberlain, Co-founder, Interviewed on MDA Quest Podcast

Parent Project Muscular Dystrophy Funds Kinea Bio

Jeffrey Chamberlain, Co-founder, Receives Muscular Dystrophy Association Legacy Award

Jeffrey Chamberlain, Co-founder, Elected President of American Society for Gene and Cell Therapy

Hichem Tasfaout, Contributing Scientist, Presents at Prestigious ASGCT Presidential Symposium at Annual ASGCT Meeting

The Speak Foundation Funds Kinea Bio

CureLGMD2i Funds Kinea Bio